Based on the similar role of DGAT genes in TAG accumulation, clinical application of inhibitors targeting these two DGAT isoforms has been attempted in nonalcoholic fatty liver disease. This evidence concerns the gene DGAT1 and metabolic dysfunction-associated steatotic liver disease.